HIGHLIGHTS
- who: Nathan T. Bain from the Institute, Australia The University of Melbourne, Australia have published the article: Minimal residual disease in EGFR-mutant non-small-cell lung cancer, in the Journal: (JOURNAL)
- what: EGFR-TKI therapy remains the mainstay of first-line treatment for EGFR-mutant NSCLC however this rarely leads to cure as acquired resistance invariably develops.
- how: The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
SUMMARY
Like . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.